BioCryst
Manufacturing · North Carolina, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
4505 Emperor Blvd Ste 200, Durham, North...Phone Number
(919) 859-1302Website
www.biocryst.comRevenue
$885.7 MillionStock Symbol
BCRXIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
5
1
2
1
1
1
About BioCryst
BioCryst Pharmaceuticals is a biotechnology company that designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. BioCryst Pharmaceuticals is headquartered in Durham, North Carolina.Explore more
BioCryst Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BioCryst your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
BioCryst, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at BioCryst
Earning: See what the market has to say on BioCryst recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when BioCryst launches new products
Click to see if BioCryst had a recent Job posting/layoffs
Funding: Get notified immidiatlly once BioCryst has new funding data
Check out if BioCryst is spiking on competitors!
Website visits: Recent activity has been detected on your website
Check if BioCryst has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to BioCryst
Compare insights from companies similar to BioCryst, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
BioCryst is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
BioCryst is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about BioCryst.
BioCryst financials insights
Gather financial insights about BioCryst, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Grant
$4.1M
Grant
$2.4M
2016
Debt
$23M
2018
Grant
$3.5M
2019
Debt
$100M
Stock Offering
$63M
2021
Other Financing Round
$350M
2023
Debt
$450M
BioCryst Tech Stack
A closer look at the technologies used by BioCryst
See more technologies
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Project
plans to commercialize navenibart as a 2-milliliter auto-injector administered either once every 3 months or twice every 6 months, primarily targeting the approximately 5,000 patients expected to still be on TAKHZYRO who may switch for an equivalent efficacy profile and a more favorable dosing schedule.
Pharmaceuticals
Project
BioCryst is targeting approximately 5,000 US patients currently on injectable prophylaxis therapy as the primary commercial opportunity for navenibart, a kallikrein inhibitor featuring a citric acid-free formulation with no injection site pain and a 3- and 6-month dosing profile.
Pharmaceuticals
Earnings
BioCryst has provided 2026 financial guidance of $635 to $660 million in revenue and $450 to $470 million in non-GAAP operating expenses, implying approximately $165 to $210 million in operating profit.
Earnings, Financial Planning, Forecasting, Finance, Financial Strategy
Project
Medical Research
BioCryst News & Media
BioCryst Appoints David W. Jenkins as Chief Scientific Officer
RESEARCH TRIANGLE PARK, N.C., July 15, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) (“BioCryst” or the “Company”) today announced the appointment of David W. Jenkins, MA, PhD, to the newly created position of Chief Scientific Officer, effective immediately, reporting to Dr. Sandeep Menon, Chief Research and Development Officer. In this role, Dr. Jenkins will build and lead an efficient research team focused on leveraging external innovation, capabilities and partnershipBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted nine newly-hired employees stock options to purchase an aggregate of 33,950 shares, and restricted stock units (RSUs) covering an aggregate of 91,750 shares, of BioCryst common stock. The options and RSUs were granted as of July 1, 2026, as inducements material to each employee entering into employmeBioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility
—Advances strategic shift toward a disciplined research model prioritizing external innovation to accelerate rare disease pipeline growth—BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting
— Growing body of ORLADEYO® clinical data and real-world evidence demonstrates consistent reductions in HAE attack burden and healthcare utilization across diverse patient populations
Read more news
Top Manufacturing Companies
Frequently Asked Questions Regarding BioCryst
Sign Up For FreeTo access detailed company insights
BioCryst Pharmaceuticals is a biotechnology company that designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. BioCryst Pharmaceuticals is headquartered in Durham, North Carolina.... Read More
